摘要 |
The present invention relates to an oral formulation to lower serum or hepatic lipid and triglyceride concentrations, hepatic inflammation and/or insulin resistance in a patient comprising live feruloyl esterase producing microorganisms alone or in association with a pharmaceutically acceptable carrier resistant to gastric conditions, and wherein the microorganisms are wild type, genetically modified, or combination thereof. The present invention is also directed to an oral formulation to lower serum or hepatic lipid and triglyceride concentrations, hepatic inflammation and/or insulin resistance in a patient, which comprises polymeric microcapsules containing live feruloyl esterase producing microorganisms in suspension in a pharmaceutically acceptable carrier, wherein said microcapsules are semipermeable and resistant to gastro-intestinal conditions, and wherein said microorganism are wild type, genetically modified, or combination thereof as well as methods of preventing or improving liver diseases and disorders and uses thereof. |